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ABSTRACT
The aim of this study was to characterise community-acquired pneumonia (CAP) caused by atypical
pathogens by combining distinctive clinical and epidemiological features and novel biological markers.
A population-based prospective study of consecutive patients with CAP included investigation of
biomarkers of bacterial infection, e.g., procalcitonin, C-reactive protein and lipopolysaccharide-binding
protein (LBP) levels. Clinical, radiological and laboratory data for patients with CAP caused by atypical
pathogens were compared by univariate and multivariate analysis with data for patients with typical
pathogens and patients from whom no organisms were identiﬁed. Two predictive scoring models were
developed with the most discriminatory variables from multivariate analysis. Of 493 patients, 94 had
CAP caused by atypical pathogens. According to multivariate analysis, patients with atypical
pneumonia were more likely to have normal white blood cell counts, have repetitive air-conditioning
exposure, be aged <65 years, have elevated aspartate aminotransferase levels, have been exposed to
birds, and have lower serum levels of LBP. Two different scoring systems were developed that predicted
atypical pathogens with sensitivities of 35.2% and 48.8%, and speciﬁcities of 93% and 91%,
respectively. The combination of selected patient characteristics and laboratory data identiﬁed up to
half of the cases of atypical pneumonia with high speciﬁcity, which should help clinicians to optimise
initial empirical therapy for CAP.
Keywords Atypical pneumonia, community-acquired pneumonia, diagnosis, identiﬁcation, scoring models,
variables
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INTRODUCTION
Selection of empirical therapy for community-
acquired pneumonia (CAP) has become compli-
cated by the marked increase in b-lactam and
macrolide resistance among strains of Streptococ-
cus pneumoniae, and by the concerns about atyp-
ical pathogens (e.g., Mycoplasma pneumoniae,
Chlamydophila spp. and Legionella spp.) [1–6]. No
general agreement currently exists concerning the
selection of the antimicrobial regimen for all
patient groups. UK guidelines for outpatients
with non-severe pneumonia advocate initial ther-
apy with amoxycillin (http://www.brit-thoracic.
org/guidelines), despite the high frequency of
atypical organisms [1–4]. In contrast, North
American guidelines still recommend monothera-
py with macrolides for many outpatients [5],
which is an approach that can be questioned in
view of the increasing rates of resistance among
pneumococci [6]. In view of these uncertainties,
clinicians may decide to provide empirical ther-
apy targeted against both standard pathogens and
atypical organisms for patients with CAP by
prescribing combined therapy with a b-lactam
and a macrolide, or monotherapy with a respir-
atory ﬂuoroquinolone. Although initial empirical
Corresponding author and reprint requests: M. Masia´, Unidad
de Enfermedades Infecciosas, Hospital General Universitario
de Elche, Camı´ de la Almazara 11, 03203 Elche, Alicante, Spain
E-mail: marmasia@ya.com
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
therapy for patients who require admission to
hospital may require broad-spectrum coverage,
overuse of antibiotics for all patients with CAP
might lead to increasing drug resistance during
the next few years [6,7].
Atypical organisms are now considered to be
an important cause of CAP, being implicated in
20–40% of CAP cases [1–4]. Unfortunately, cov-
erage of atypical pathogens remains empirical in
most cases because of an absence of rapid,
standardised diagnostic tests. Although molecu-
lar techniques, e.g., PCR with respiratory secre-
tions, are promising [5], their accuracy and
reproducibility have yet to be established, and
no commercial assays are currently available for
use by clinical microbiology laboratories. In this
scenario, the availability of predictors of infec-
tion by atypical organisms would be of interest,
since they could help determine the initial
therapy for cases of CAP. However, epidemio-
logical studies have shown that single clinical,
radiological or laboratory parameters have lim-
ited value in predicting the microbial aetiology
of CAP and in characterising atypical pneumonia
[4,8–10].
Rapid diagnostic tests for bacterial pneumonia,
e.g., the pneumococcal urinary antigen test [11],
have become available recently, and novel serum
biomarkers of bacterial infection, e.g., procalcito-
nin (PCT), have been described [12,13]. The
information provided by these tests could be
useful as additional criteria for differentiating
between atypical and classical bacterial aetiology
in CAP. The present study describes a large
prospective investigation of CAP in which the
clinical features of the patients were recorded,
and extensive laboratory investigations, including
determinations of pneumococcal urinary antigen
and serum biomarkers of bacterial infection, were
performed [14]. Three previous reports have
evaluated the Binax immunochromatographic
assay for detection of S. pneumoniae urinary anti-
gen in the same patient cohort [15], together with
the usefulness of lipopolysaccharide-binding pro-
tein (LBP) [16] and PCT [17] as predictors of
aetiology and prognosis. The objective of the
present study was to characterise atypical pneu-
monia by combining laboratory data with the
epidemiological and clinical features of the
patients. In addition, a scoring system was
devised to compare CAP caused by atypical
pathogens with other causes of CAP in order to
determine the variables that were most effective
in discriminating atypical pathogens from other
organisms.
PATIENTS AND METHODS
Setting and population studied
This prospective study was conducted at Hospital General
Universitario de Elche, a 430-bed university-afﬁliated teaching
hospital serving a population of 250 000 in Alicante, a province
on the Mediterranean coast of Spain. All adult patients (aged
‡15 years) with signs and symptoms compatible with pneu-
monia during two consecutive periods of 12 months (from 15
October 1999 to 14 October 2000, and from 15 October 2000 to
14 October 2001) were eligible for inclusion in the study. The
study was approved by the local ethical committee, and
informed consent was obtained from all the patients. CAP was
deﬁned as an acute illness associated with at least one of the
following signs or symptoms: fever (measured by axillary
temperature, which is common clinical practice in our centre);
new cough, with or without sputum production; pleuritic
chest pain; dyspnoea; and altered breath sound on ausculta-
tion, plus a chest radiograph showing an opacity compatible
with the presence of acute pneumonia. Patients with a
provisional diagnosis of CAP were seen within 48 h by a
study investigator to conﬁrm the diagnosis. Patients with
previous hospitalisation within 2 weeks of the current diag-
nosis of pneumonia were excluded.
Demographical and clinical data were collected using a
written standardised questionnaire. Among the clinical data,
air-conditioning exposure was deﬁned as repetitive and
prolonged (several hours a day) exposure at home or at work,
and exposure to birds was deﬁned as having birds at home or
at work, or frequent contact with birds as a hobby. The severity
of pneumonia was calculated using the Pneumonia Patient
Outcome Research Team (PORT) severity index (PSI) [18],
which classiﬁes patients, according to outcome, in ﬁve risk
classes (class I includes patients with the most favourable
prognosis, and class V those with the poorest prognosis). All
patients were followed for at least 4 weeks or until death. A
repeat chest radiograph and a blood sample were obtained
2–4 weeks after the initial diagnosis of CAP.
Microbiological investigations
The laboratory investigation for a patient with CAP has been
described previously [14]. In brief, it included obtaining
sputum samples for Gram’s stain and culture, two blood
samples for culture, a urine sample for detection of Legionella
pneumophila and S. pneumoniae antigens, and serum samples
for detection of antibodies against atypical pathogens and
viruses (taken during the acute stage of illness and at least
2 weeks later).
A complement ﬁxation test was performed to detect
antibodies against M. pneumoniae, Chlamydophila spp., Coxiella
burnetii, inﬂuenza viruses A and B, respiratory syncytial virus
and adenovirus. An indirect immunoﬂuorescence test was
used to detect antibodies to L. pneumophila, and a microim-
munoﬂuorescence test was used to detect antibodies against
Chlamydophila pneumoniae, Chlamydophila psittaci and Chlamydo-
phila trachomatis.
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Criteria for aetiological diagnosis
The following criteria were used to classify a pneumonia as
being of known aetiology: (i) a four-fold or greater antibody
rise for M. pneumoniae, Chl. psittaci, Cox. burnetti, inﬂuenza
viruses A and B, parainﬂuenza virus, respiratory syncytial
virus or adenovirus; (ii) a four-fold rise in microimmuno-
ﬂuorescence antibody titre to ‡1:128, or the presence of IgM
antibodies (>1:20) for Chl. pneumoniae; (iii) isolation of the
organism from respiratory samples, or Legionella antigen
detected in urine, or a four-fold or greater rise in immunoﬂu-
orescence antibody titre for L. pneumophila; (iv) isolation of the
organism from blood or pleural ﬂuid, or isolation as the
predominant organism from a qualiﬁed sputum sample, or
antigen detected in urine for S. pneumoniae; and (v) isolation of
the organism from blood or pleural ﬂuid, or isolation as the
predominant organism from a qualiﬁed sputum sample for
Haemophilus inﬂuenzae, Moraxella catarrhalis, Staphylococcus
aureus and other bacteria, including Gram-negative entero-
bacteria. Cases that fulﬁlled the aetiological diagnostic criteria
described above for more than one pathogen were considered
to be mixed pneumonia, and included the following combi-
nations of two or more pathogens: standard bacterial path-
ogens plus atypical organisms; atypical organisms plus
viruses; two or more standard bacterial pathogens; two or
more atypical organisms; and two or more viruses. Cases that
did not fulﬁl the aetiological diagnostic criteria described
above were considered to be pneumonia of unknown
aetiology.
Detection of LBP, C-reactive protein (CRP) and PCT
During the ﬁrst 12-month period (15 October 1999 to 14
October 2000), patients included in the study had a blood
sample collected within 24 h of fulﬁlling the diagnostic criteria
for pneumonia in order to measure LBP, CRP and PCT levels.
Serum samples were collected and stored at )80C until
analysed in May 2003. LBP levels were measured using a
commercially available assay (Immulite LBP; DPC, Los Ange-
les, CA, USA) according to the manufacturer’s guidelines,
using an Immulite immunoanalyser (DPC) with a limit of
detection of 0.2 mg ⁄L [19]. CRP was measured using a Behring
nephelometer II (Behring Co., Marburg, Germany), with a limit
of detection of 3.67 mg ⁄L [20]. PCT levels were measured with
a monoclonal immunoluminometric assay (Liaison Brahms
PCT; Brahms Diagnostica, Berlin, Germany), with a limit of
detection of 0.1 lg ⁄L [21]. All biochemical tests were per-
formed in a blinded fashion, without knowing the results of
other microbiological investigations.
Data analysis
Statistical analysis was performed using SPSS v.11.5 (SPSS Inc.,
Chicago, IL, USA). For the purposes of the calculations,
patients were classiﬁed into three groups: (i) patients with
pneumonia caused by atypical pathogens, including three
patients with mixed pneumonia caused by two atypical
organisms; (ii) patients with pneumonia caused by standard
pathogens; and (iii) patients with pneumonia of unknown
aetiology. Clinical and laboratory data were compared as
dichotomous variables using the chi-square test, with p <0.05
considered as signiﬁcant. Variables found to be statistically
signiﬁcant in the univariate analysis were included in a
multivariate stepwise logistic regression model. Two logistic
regression models were developed, the ﬁrst comparing atyp-
ical with other microbial causes of pneumonia, and the second
comparing atypical pneumonia with pneumonia of unknown
aetiology. A scoring system was then constructed that inclu-
ded four signiﬁcant variables from the multivariate analyses,
which were allocated one point each. Different combinations
were assessed, until the best sensitivity and speciﬁcity for the
scoring system were obtained. Two separate models were
assessed, with the ﬁrst comprising all 493 patients enrolled
during the two study periods, and the second including only
the 240 patients enrolled during the ﬁrst 12-month study
period, for whom serum biomarkers of bacterial infection were
available. Receiver operating characteristic curves were used
to describe the sensitivity and speciﬁcity of the classiﬁcation of
the aetiology of pneumonia for each scoring system.
RESULTS
Of 516 patients with signs and symptoms com-
patible with pneumonia, 23 were found subse-
quently not to have CAP (eight had lower
respiratory tract infection without pneumonia,
seven had heart failure, two had pulmonary
embolism, two had lung cancer, one had
bronchiectasis, one had atelectasis, one had
pulmonary ﬁbrosis, and one had pulmonary
haemorrhage), leaving 493 patients in the study
cohort. The ﬁrst 12-month period (15 October
1999 to 14 October 2000) included 240 patients,
and the second 12-month period (15 October 2000
to 14 October 2001) included 253 patients. Base-
line characteristics of the patients, listed accord-
ing to aetiological group, are summarised in
Table 1.
Aetiological agents identiﬁed
Aetiological agents were found for 250 (50.7%)
patients, including 140 bacterial, 110 atypical and
30 viral pathogens. In 243 (49.3%) cases, the
aetiology remained unknown after microbiologi-
cal investigation; in these patients, the clinical
diagnosis of pneumonia was conﬁrmed by sub-
sequent follow-up evaluations. Table 2 shows the
aetiological organisms identiﬁed.
Analysis group
Of 95 patients with pneumonia caused by atypical
organisms, one was excluded because of an
indeterminate pneumococcal urinary antigen,
leaving 94 patients in the analysis group, of
whom three had mixed infections caused by two
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atypical organisms. Forty-seven of these patients
were enrolled during the ﬁrst period of the study.
The atypical pathogens identiﬁed are listed in
Table 2, and the demographical and clinical char-
acteristics of the patients are summarised in
Table 1. No patient with atypical pneumonia died
within the 4-week follow-up period.
Since pneumonia caused by Legionella spp.
might have a distinctive clinical presentation,
clinical and laboratory variables of patients with
CAP caused by Legionella spp. were compared
with those of patients with other causes of
atypical CAP. Patients with Legionella pneu-
monia were more likely to have chronic
obstructive pulmonary disease (p 0.01), exposure
to air-conditioning (p <0.001) and elevated
aspartate aminotransferase (AST) levels (p 0.03),
and were less likely to belong to low PSI risk
classes (I–II) (p 0.05). One case of Legionella
pneumonia was a severe illness that required
mechanical ventilation, but had a favourable
outcome.
Table 1. Demographical and clinical characteristics of patients with community-acquired pneumonia (n = 493), listed
according to aetiological group
Characteristic
Atypical
(n = 94a)
pathogens
Standard
bacterial
pathogens
(n = 111)
Other
pathogensb
(n = 45)
Unknown
aetiology
(n = 243)
Male, no. patients (%) 63 (67) 70 (63.1) 26 (57.8) 149 (61.3)
Age (years), mean (range) 46 (15–86) 59.1 (15–90) 58.8 (15–93) 59.1 (15–94)
PSI score, median (IQR) 48 (23.5–72.3) 79 (44–102.3) 78 (42–101) 69 (42–90)
Risk classes I–II 70 (74.5) 50 (45) 20 (44.4) 128 (52.6)
Risk class III 11 (11.7) 24 (21.6) 9 (20) 59 (24.3)
Risk classes IV–V 13 (13.8) 36 (32.4) 16 (35.5) 56 (23)
Co-morbidity, no. patients (%) 25 (26.6) 65 (58.6) 28 (62.2) 109 (44.9)
Diabetes mellitus 17 (18.1) 26 (23.4) 7 (15.6) 48 (19.8)
COPD 10 (10.4) 29 (26.1) 10 (22.2) 50 (20.6)
Otherc 8 (8.5) 50 (45) 16 (35.6) 48 (19.8)
Risk-factors, no. patients (%)
Smoking 23 (24.5) 24 (21.6) 17 (37.8) 47 (19.3)
Alcohol 10 (10.6) 17 (15.3) 7 (15.6) 29 (11.9)
Exposure to birds 35 (36.5) 20 (18) 7 (15.6) 61 (25.1)
Air-conditioning exposured 14 (14.6) 5 (4.5) 0 18 (7.4)
Hospital admission, no. patients (%) 56 (59.6) 87 (78.4) 36 (80) 182 (74.9)
Previous antibiotic treatment, no. patients (%) 29 (30.9) 16 (14.4) 8 (17.8) 61 (25.1)
Clinical presentation and laboratory
data, no. patients (%)
Dyspnoea, moderate or severe 23 (24.5) 47 (42.3) 22 (48.9) 95 (39.1)
Pleuritic chest pain, moderate or severe 21 (22.4) 51 (45.9) 21 (46.6) 99 (40.7)
Headache, moderate or severe 19 (20.2) 12 (10.8) 6 (13.3) 24 (9.9)
Diarrhoea 12 (12.8) 4 (3.6) 3 (6.6) 16 (6.6)
Confusion 5 (5.3) 17 (15.3) 12 (26.7) 24 (9.9)
Purulent sputum production 35 (37.2) 70 (63) 34 (75.5) 121 (49.8)
WBC ⁄mm3 8200 (6575–12 100) 13 550 (8963–17 930) 12 900 (9785–16 500) 11 600 (8208–16 000)
Neutrophil count ⁄mm3 6610 (4700–10 150) 11 645 (7575–15 673) 11 200 (7835–14 550) 9270 (6000–13 455)
LBPe serum levels (mg ⁄L) 9.2 (6.9–13.6) 20.2 (10.7–32.7) 19.8 (11.9–36.8) 14.7 (9.6–31)
CRPe serum levels (mg ⁄L) 3.67 (3.67–12.1) 13.4 (4.4–115.5) 40 (9.8–122) 12 (3.7–80.7)
Procalcitoninf serum levels (lg ⁄L) 0.10 (0.10–0.11) 0.10 (0.10–0.31) 0.10 (0.10–0.16) 0.10 (0.10–0.15)
Antibiotic treatment prescribed,
no. patients (%)
b-Lactam alone 15 (16) 27 (24.3) 17 (37.8) 49 (20.2)
Macrolide alone 12 (12.8) 8 (7.2) 0 26 (10.7)
Fluoroquinoloneg 22 (23.4) 18 (16.2) 4 (8.9) 41 (16.9)
Combined therapyh 40 (42.6) 48 (43.2) 17 (37.8) 115 (47.3)
Other ⁄unknown 4 (4.3) 8 (7.2) 7 (15.6) 12 (4.9)
Outcome, no. patients (%)
Pleural effusion 5 (5.3) 19 (17.1) 8 (17.8) 27 (11.1)
Atelectasis 5 (5.3) 9 (8.1) 1 (2.2) 14 (5.8)
Mechanical ventilation 1 (1.1) 2 (1.8) 3 (6.7) 3 (1.2)
Death 0 8 (7.2) 3 (6.7) 13 (5.3)
Data for continuous variables are median values (inter-quartile range), except for age.
PSI, pneumonia PORT (patient outcome research team) severity index; IQR, inter-quartile range; COPD, chronic obstructive pulmonary disease; WBC, white blood cell count;
LBP, lipopolysaccharide-binding protein; CRP, C-reactive protein.
aThree patients with mixed pneumonia caused by two atypical organisms were also included.
bMixed pneumonia (n = 25) + viral pneumonia (n = 20).
cCongestive heart failure, chronic liver disease, neoplasia, immunosuppression, altered mental status.
dRepetitive exposure at work or at home.
eData were available for 196 patients.
fData were available for 185 patients.
gLevoﬂoxacin or moxiﬂoxacin.
hb-Lactam plus a macrolide.
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Signiﬁcant variables associated with CAP
caused by atypical pathogens, compared with
variables associated with other microbial causes
of pneumonia and pneumonia of unknown aeti-
ology, by univariate analysis are shown in
Table 3. PCT serum levels were determined for
185 patients. In patients with atypical CAP, mean
(SD) and median values were 0.30 lg ⁄L (0.88) and
0.1 lg ⁄L, respectively, whereas mean and median
values for patients with CAP caused by other
pathogens were 0.55 lg ⁄L (1.50) and 0.1 lg ⁄L,
respectively (p 0.3).
Multivariate analysis in which the 94 patients
with CAP caused by atypical pathogens were
compared with the 156 patients with other
microbial causes of CAP revealed that patients
with pneumonia caused by atypical pathogens
were more likely to have repeated exposure
to air-conditioning (OR 9.09), normal white
blood cell (WBC) counts (OR 7.57), exposure to
birds (OR 3.73), an absence of purulent sputum
(OR 3.47), and an absence of co-morbidity
(OR 3.10) (Table 4). Multivariate analysis in
which patients with atypical CAP were compared
with patients with CAP of unknown aetiology
revealed that patients with atypical CAP were
more likely to have elevated AST levels (OR 2.65),
to be aged <65 years (OR 2.52) and to have
normal WBC counts (OR 2.36), but were less
likely to have tachypnoea (OR 0.52).
When only the 240 patients from the ﬁrst
period of the study were included in the analysis,
and LBP and CRP serum levels were added to the
multivariable logistic regression model, multiva-
riate analysis revealed that patients with pneu-
monia caused by atypical pathogens were more
likely than patients with standard pathogens to
have repeated exposure to air-conditioning
(OR 15.32), exposure to birds (OR 8.31), a PSI
score <70 (OR 8.33), an LBP value <14 mg ⁄L
(OR 7.47), an absence of purulent sputum
(OR 6.17) and elevated AST levels (OR 4.24)
(Table 5). When patients with pneumonia caused
by atypical pathogens were compared with
patients with pneumonia of unknown aetiology,
multivariate analysis showed that patients with
atypical pneumonia were more likely to be aged
<65 years (OR 6.59), to have an LBP value
<14 mg ⁄L (OR 3.94) and elevated AST levels
(OR 3.32).
Predictive modelling
A scoring system was devised that included four
of the signiﬁcant variables revealed by the two
multivariate analyses. When age <65 years, a
normal WBC count, exposure to birds, and an
elevated AST level were included, and the entire
population of 493 patients was analysed, a score
of ‡3 captured 32 of 91 patients with pneumonia
caused by atypical organisms (35.2% sensitivity),
and only 27 of 386 patients with other causes of
pneumonia (93% speciﬁcity). The area under the
curve was 0.73 (95% CI 0.67–0.79), and 477
(96.7%) patients were classiﬁed.
A second scoring system was used to analyse
only the 240 patients from the ﬁrst period of the
study. An additional variable from the univariate
analysis was incorporated, as it improved the
sensitivity and speciﬁcity of the model. When age
<65 years, LBP levels <14 mg ⁄L, exposure to
birds and a normal WBC count were included, a
score of ‡3 captured 20 of 41 patients with
pneumonia caused by atypical pathogens (48.8%
sensitivity), and only 14 of 155 patients with other
causes of pneumonia (91% speciﬁcity). The area
Table 2. Microorganisms identiﬁed in patients (n = 493)
with community-acquired pneumonia
Patient group No. of patients (%)
Bacterial pneumonia 111 (22.5)
Streptococcus pneumoniae 83 (16.8)
Pseudomonas spp. 11 (2.2)
Haemophilus spp. 9 (1.8)
Gram-negative bacilli other than Pseudomonas spp.a 5 (1.0)
Staphylococcus aureus 2 (0.4)
Moraxella catarrhalis 1 (0.2)
Pneumonia caused by atypical pathogens 91 (18.5)
Mycoplasma pneumoniae 38 (7.7)
Legionella pneumophila 21 (4.3)
Chlamydophila spp.b 30 (6.1)
Coxiella burnetii 2 (0.4)
Viral pneumonia 20 (4.1)
Inﬂuenza virus 14 (2.8)
Viruses other than inﬂuenza 6 (1.2)
Mixed pneumoniac 28 (5.7)
Pneumonia, with no pathogen identiﬁed 243 (49.3)
Total 493
aKlebsiella spp. (two cases), Escherichia coli (one case), Citrobacter spp. (one case),
Stenotrophomonas spp. (one case).
bChlamydophila pneumoniae (15 cases), Chlamydophila psittaci (nine cases). In six cases,
there was a four-fold rise in antibodies against both Chl. psittaci (complement
ﬁxation test) and Chl. pneumoniae (microimmunoﬂuorescence test).
cStreptococcus pneumoniae and Legionella pneumophila (three cases), Strep. pneumoniae
and Pseudomonas spp. (three cases), Strep. pneumoniae and Mycoplasma pneumoniae
(two cases), Strep. pneumoniae and inﬂuenza virus (two cases), M. pneumoniae and
inﬂuenza virus (two cases), L. pneumophila and Chl. pneumoniae (two cases),
Strep. pneumoniae and Haemophilus spp. (one case), Strep. pneumoniae and Staphyloc-
cus aureus (one case), Strep. pneumoniae and Klebsiella spp. (one case), Strep. pneu-
moniae and Enterobacter spp. (one case), Strep. pneumoniae and Moraxella catarrhalis
(one case), Strep. pneumoniae and Coxiella burnetii (one case), M. pneumoniae and
Haemophilus inﬂuenzae (one case), Chl. psittaci and Listeria monocytogenes (one case),
Chl. pneumoniae and Cox. burnetti (one case), L. pneumophila and inﬂuenza virus (one
case), inﬂuenza virus and varicella-zoster virus (one case), inﬂuenza virus and
respiratory syncytial virus (one case), Strep. pneumoniae, M. pneumoniae and inﬂu-
enza virus (one case),M. pneumoniae, Strep. pneumoniae and Staph. aureus (one case).
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under the curve was 0.78 (95% CI 0.70–0.86), and
196 (81.7%) of the patients were classiﬁed.
According to the PSI, the median punctuation
of patients with a score suggestive of atypical
aetiology (‡3) was 46. In patients with a score <3,
suggestive of standard aetiology, the median PSI
punctuation was 72 (p <0.001). Likewise, 83.1% of
patients with a score suggestive of atypical
aetiology had a PSI of <70 (risk classes I–II),
compared with only 48.1% of patients with a
score suggestive of non-standard aetiology
(p <0.001).
Table 3 Univariate analysis of variables associated with community-acquired pneumonia (CAP) caused by atypical vs.
standard pathogens (n = 250), and atypical pneumonia vs. pneumonia of unknown aetiology (n = 337)
Clinical feature
Atypical
pathogens
(n = 94)a
Standard
pathogens
(n = 156) OR (95% CI)b pb
Unknown
aetiology
(n = 243) OR (95% CI)c pc
Risk-factor
Age <65 years 72 ⁄ 94 (76.6) 75 ⁄ 156 (48.1) 3.54 (2.0–6.26) <0.001 126 ⁄ 243 (51.9) 3.21 (1.85–5.52) <0.001
COPD 10 ⁄ 94 (10.6) 39 ⁄ 155 (25.2) 0.35 (0.17–0.75) 0.005 50 ⁄ 243 (20.6) 0.46 (0.22–0.95) 0.03
Aspiration 0 ⁄ 92 (0) 10 ⁄ 152 (6.6) 0.79 (0.76–0.83) 0.004 16 ⁄ 235 (6.8) 0.15 (0.02–1.15) 0.04
Immunosuppression 1 ⁄ 94 (1.1) 17 ⁄ 155 (11) 0.09 (0.01–0.67) 0.002 8 ⁄ 243 (3.3) 0.32 (0.04–2.56) 0.4
No co-morbidity 70 ⁄ 94 (74.5) 75 ⁄ 155 (48.1) 3.11 (1.78–5.45) <0.001 145 ⁄ 243 (59.7) 1.97 (1.16–3.35) 0.01
Exposure to air-conditioningd 14 ⁄ 92 (15.2) 5 ⁄ 152 (3.3) 5.26 (1.83–15.2) 0.001 18 ⁄ 235 (7.7) 2.16 (1.03–4.57) 0.06
Exposure to birds 34 ⁄ 92 (37) 27 ⁄ 152 (17.8) 2.72 (1.50–4.90) 0.001 61 ⁄ 235 (26) 1.67 (1–2.79) 0.05
Signs ⁄ symptoms
Fevere 58 ⁄ 94 (61.7) 69 ⁄ 155 (44.5) 2.01 (1.19–3.39) 0.009 112 ⁄ 243 (46.1) 1.88 (1.16–3.07) 0.01
Tachypnoeaf 21 ⁄ 94 (22.3) 66 ⁄ 155 (42.6) 0.41 (0.23–0.73) 0.003 99 ⁄ 243 (40.7) 0.44 (0.26–0.76) 0.003
Headache 39 ⁄ 94 (41.5) 32 ⁄ 156 (20.5) 2.75 (1.56–4.84) <0.001 56 ⁄ 243 (23) 2.37 (1.43–3.93) 0.001
Absence of purulent sputum 59 ⁄ 94 (62.8) 51 ⁄ 155 (32.9) 3.4 (2.01–5.87) < 0.001 121 ⁄ 242 (50) 1.69 (1.04–2.75) 0.03
Laboratory ﬁndings
Leukocytosisg 34 ⁄ 94 (36.2) 115 ⁄ 156 (73.7) 0.20 (0.12–0.35) <0.001 153 ⁄ 243 (63) 0.33 (0.20–0.55) <0.001
Neutrophiliah 64 ⁄ 93 (68.8) 137 ⁄ 155 (88.4) 0.29 (0.15–0.56) <0.001 197 ⁄ 242 (81.4) 0.5 (0.29–0.87) 0.01
AST >35 U ⁄L 27 ⁄ 93 (29.0) 26 ⁄ 156 (16.7) 2.05 (1.11–3.78) 0.02 34 ⁄ 243 (14) 2.51 (1.41–4.74) 0.002
LBP <14 mg ⁄L 31 ⁄ 41 (75.6) 24 ⁄ 70 (34.3) 5.94 (2.40–14.14) <0.001 39 ⁄ 85 (45.9) 3.66 (1.59–8.39) 0.002
CRP <50 mg ⁄L 35 ⁄ 41 (85.4) 40 ⁄ 68 (58.8) 4.08 (1.51–11.01) 0.005 58 ⁄ 84 (69) 2.62 (0.98–6.98) 0.05
PSI score <70 (I ⁄ II) 69 ⁄ 94 (73.4) 67 ⁄ 155 (43.2) 3.63 (2.10–6.33) <0.001 124 ⁄ 243 (51) 2.65 (1.57–4.47) <0.001
Data are number (%) of patients. All variables are dichotomous, and their presence is compared with their absence. An OR >1 indicates an association with CAP caused by
atypical pathogens, and an OR <1 indicates an association with other causes of CAP.
COPD, chronic obstructive pulmonary disease; AST, aspartate aminotransferase; LBP, lipopolysaccharide-binding protein; CRP, C-reactive protein; PSI, pneumonia PORT
(patient outcome research team) severity index.
aThree patients with mixed pneumonia caused by two or more atypical organisms were also included.
bComparison between patients with CAP caused by atypical vs. standard pathogens.
cComparison between patients with CAP caused by atypical pathogens vs. CAP of unknown aetiology.
dRepetitive exposure at work or at home.
eAxillary body temperature ‡38C.
fRespiratory frequency >18 respirations ⁄min.
gWhite blood cell count >10 · 109 cells ⁄L.
hNeutrophil count >5 · 109 cells ⁄L.
Table 4. Multivariate analysis comparing clinical and
laboratory features of patients with community-acquired
pneumonia caused by atypicala vs. standard pathogensb,
and atypical pneumonia vs. pneumonia of unknown
aetiology
Variable ORb 95% CIb pb ORc 95% CIc pc
Exposure to air-conditioningd 9.09 2.56–32.25 0.001
WBC count <10 000 ⁄mm3 7.57 3.81–15.01 <0.001
Exposure to birds 3.73 1.75–7.95 0.001
Absence of purulent sputum 3.47 1.79–6.76 <0.001
Absence of co-morbidity 3.10 1.57–6.10 0.001
AST >35 U ⁄L 2.65 1.40–5.0 0.003
Age <65 years 2.52 1.37–4.64 0.003
Tachypnoeae 0.52 0.28–0.96 0.03
WBC, white blood cell count; AST, aspartate aminotransferase.
aThree patients with mixed pneumonia caused by two atypical organisms were also
included.
bComparison between patients with pneumonia caused by atypical pathogens vs.
other microbial causes of pneumonia.
cComparison between patients with pneumonia caused by atypical pathogens vs.
pneumonia of unknown aetiology.
dRepetitive exposure at work or at home.
eRespiratory frequency >18 respirations ⁄min.
Table 5. Multivariate analysis of the clinical and laborat-
ory features of 240 patients with community-acquired
pneumonia caused by atypicala pathogens, compared with
patients with pneumonia caused by standard pathogensb,
and with patients with pneumonia of unknown aetiologyc
Variable ORb 95% CIb pb ORc 95% CIc pc
Exposure to air-
conditioningd
15.32 2.02–116.03 0.008
PSI score <70
(risk classes I–II)
8.33 2.43–28.57 0.001
Exposure to birds 8.31 2.14–32.37 0.002
LBP <14 mg ⁄L 7.47 2.32–24.09 0.001 3.94 1.55–10.02 0.004
Absence of
purulent sputum
6.17 1.95–19.61 0.002
AST >35 U ⁄L 4.24 1.08–16.67 0.03 3.32 1.13–9.80 0.02
Age <65 years 6.59 2.52–17.25 <0.001
PSI, pneumonia PORT (patient outcome research team) severity index; LBP,
lipopolysaccharide-binding protein; AST, aspartate aminotransferase.
aThree patients with mixed pneumonia caused by two atypical organisms were also
included.
bComparison between patients with pneumonia caused by atypical pathogens vs.
patients with other microbial causes of pneumonia.
cComparison between patients with pneumonia caused by atypical pathogens vs.
patients with pneumonia of unknown aetiology.
dRepeated exposure at work or at home.
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DISCUSSION
This study identiﬁed several clinical and biologi-
cal predictors of atypical pneumonia. Although
atypical pneumonia was difﬁcult to differentiate
from other causes of pneumonia on clinical
grounds, a combination of epidemiological, clin-
ical and laboratory data greatly improved the
ability to predict CAP caused by atypical patho-
gens. An age <65 years, exposure to birds, a
normal WBC count, an elevated AST level and an
LBP serum level of <14 mg ⁄L were the best
variables to include in a predictive index for
atypical pneumonia. In addition, as all the
patients classiﬁed as having atypical CAP were
negative with the pneumococcal urinary antigen
assay, this test was also incorporated into the
predictive models. Using these variables, two
highly speciﬁc clinical indices for predicting
atypical aetiology in patients with CAP were
developed. Although the sensitivity was low, up
to half of the candidates for receiving targeted
therapy with macrolides could be identiﬁed,
thereby avoiding unnecessary use of b-lactams
or ﬂuoroquinolones and decreasing the risks of
antibiotic resistance and side-effects, as well as
healthcare-related costs. Since the incidence of
CAP in developed countries is 11–12 cases ⁄
1000 individuals ⁄year [22], and atypical organ-
isms may account for up to 50% of all cases of
CAP [2], this proportion represents a signiﬁcant
number of patients.
Interestingly, repeated exposure to air-condi-
tioning was one of the independent variables
associated with atypical aetiology. This associ-
ation has not been reported previously. When the
clinical characteristics of the patients with pneu-
monia caused by Legionella spp. were analysed
individually, exposure to air-conditioning was
associated strongly with infection caused by this
microorganism (42.9% of exposed patients had
Legionella pneumonia vs. 7% of exposed patients
with pneumonia caused by other atypical patho-
gens; data not shown). Although it is well-known
that cooling towers constitute a source of Legion-
naires’ disease in the community, domestic air-
conditioning exposure has not been identiﬁed
previously as a risk-factor. In southern European
countries, exposure to air-conditioning is com-
mon at work or at home, especially during the
summer months, and most of the patients ex-
posed had acquired pneumonia between May
and October (data not shown). The higher fre-
quency of exposure to air-conditioning among
patients with atypical CAP might therefore reﬂect
the inﬂuence of the group of patients with
Legionella pneumonia. In addition, exposure to
birds was one of the risk-factors associated with
atypical pneumonia. As expected, patients with
pneumonia caused by Chl. psittaci constituted the
majority of patients exposed to birds among the
sample of patients with atypical CAP (69.2% vs.
31.6%, respectively, p 0.01; data not shown).
The results of the present study revealed that
36% of all diagnosed cases of CAP were caused
by atypical pathogens, in line with the ﬁgures
reported by other investigators [1–4]. It is of note
that 23% of patients with atypical pneumonia
were aged >65 years, and 25% had an associated
co-morbid condition. Atypical pneumonia is
usually considered to be more frequent among
younger patients without co-morbidity, but sig-
niﬁcant incidence rates have also been described
in the elderly [23,24] and in patients with co-
morbidity [25]. Likewise, although atypical path-
ogens, other than Legionella spp., have usually
been associated with mild-to-moderate illness,
severe cases of CAP caused by atypical organ-
isms, other than Legionella spp., that require
admission to an intensive care unit have been
reported [26]. In the present study, patients with
atypical pneumonia had a disease of low severity,
as assessed by the PSI, and all had a favourable
outcome.
Among the atypical pathogens, M. pneumoniae,
Chl. pneumoniae and L. pneumophila caused the
majority of cases. Although M. pneumoniae has
long been considered to be the main causative
atypical organism [2,3], Chl. pneumoniae has
reached a proportion comparable to, or higher,
than that of Mycoplasma in some studies [27],
whereas in other cohorts it has been observed
much more rarely [3]. The exact signiﬁcance of
Chl. pneumoniae remains to be elucidated,
although the lack of a reference standard for the
diagnosis may account, in part, for the wide
variation in the reported incidence rates. In the
present cohort, using the currently recommended
criteria to diagnose Chl. pneumoniae infection [5],
Chl. pneumoniae was found to be a signiﬁcant
pathogen in CAP, but its frequency was lower
than that of M. pneumoniae, and much lower than
that reported in other studies of pneumonia
[4,27].
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Increasing reports of mixed organisms causing
pneumonia [2,28,29], together with recent retro-
spective studies suggesting that dual antibiotic
therapy may reduce mortality in patients with
CAP admitted to hospital [30,31], could cast
doubt on the wisdom of monotherapy with
macrolides. The present analysis only investi-
gated patients with monomicrobial pneumonia
caused by atypical pathogens, and excluded cases
of mixed infection. Nevertheless, despite the
extensive microbiological investigations per-
formed in the study, an associated bacterial
infection could have been missed in some patients
classiﬁed as having pneumonia caused by atyp-
ical organisms alone. Additionally, the use of
alternative diagnostic techniques, e.g., PCR or
viral cultures from respiratory secretions, or
serological tests other than complement ﬁxation,
might have contributed to a decrease in the high
proportion of patients without a ﬁnal microbial
diagnosis. This may have led to greater accuracy,
as patients with pneumonia of unknown aetiol-
ogy represent a miscellaneous aetiological group
for which interpretation of data is uncertain.
The study also had other limitations. Although
the predictors were generated from a heterogene-
ous study population with a broad clinical and
microbial spectrum of CAP, some subgroups may
not have been represented sufﬁciently; thus, the
predictors may not be applicable to all patient
populations. Some of the biomarkers, e.g., LBP,
currently have limited practical usefulness; LBP
determination is a time-consuming test, and
experience in its interpretation in the ﬁeld of
pneumonia is very limited. Finally, the clinical
and biological predictors of atypical pneumonia,
and the estimation of the sensitivity and specif-
icity of their combination, were determined using
the same sample of patients. Therefore, the
current predictive models should be treated as
developmental rather than deﬁnitive.
In summary, several clinical and epidemiolog-
ical features appear to characterise infections
caused by atypical pathogens, but very few are
useful for predicting atypical CAP. Indeed, some
of these features are linked more frequently with
particular atypical microorganisms. However, the
combination of selected patient characteristics
with additional diagnostic tests could help clini-
cians to discriminate CAP caused by atypical
pathogens with a high speciﬁcity. The study
conﬁrmed that microbial diagnosis of CAP
remains problematic. New microbiological tech-
niques are needed urgently to improve the detec-
tion of microorganisms causing CAP. Meanwhile,
the presumptive identiﬁcation of patients with
pneumonia caused by atypical pathogens might
help to optimise initial therapy for CAP by
allowing tailored antimicrobial coverage with
macrolides.
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